The historical rank and industry rank for Amicus Therapeutics's PB Ratio or its related term are showing as below:
FOLD'
s PB Ratio Range Over the Past 10 Years
Min: 1.92 Med: 6.77 Max: 36.16
Current: 18.49
During the past 13 years, Amicus Therapeutics's highest PB Ratio was 36.16. The lowest was 1.92. And the median was 6.77.
FOLD's PB Ratio is ranked worse than 95.42% of 1311
companies
in the Biotechnology industry
Industry Median: 2.37
vs FOLD: 18.49
During the past 12 months, Amicus Therapeutics's average Book Value Per Share Growth Rate was 24.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -25.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -9.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amicus Therapeutics was 50.70% per year. The lowest was -38.30% per year. And the median was -17.50% per year.
Back to Basics: PB Ratio
Amicus Therapeutics PB Ratio Historical Data
The historical data trend for Amicus Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amicus Therapeutics's PB Ratio
For the Biotechnology subindustry, Amicus Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amicus Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Amicus Therapeutics's PB Ratio falls into.
Amicus Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Amicus Therapeutics (NAS:FOLD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Amicus Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of Amicus Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Amicus Therapeutics (Amicus Therapeutics) Business Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FOLD has been successfully added to your 